文献速递乳腺介入USMR

界定乳腺冷冻消融治疗成功:乳腺癌根治性与姑息性治疗指南

Defining Breast Cryoablation Treatment Success: A Guide for the Curative and Palliative Treatment of Breast Cancer.
PubMed 文献 · Acad Radiol · 2024-08-05

该回顾性分析纳入2021—2024年接受超声或MRI引导下乳腺冷冻消融的乳腺癌患者,将消融分为根治性与姑息性,以同时达到手术目标和患者个体化治疗目标定义治疗成功。随访影像显示根治性14例中13例成功,姑息性13例全部成功,并发症仅2例皮肤冻伤。

要点

  • 治疗成功定义为同时达到手术目标与患者个体化治疗目标,需区分根治性与姑息性消融。
  • 随访27例中,根治性14例14个肿瘤13例成功,姑息性13例18个病灶全部成功。
  • 并发症仅2例皮肤冻伤(1例轻度、1例中度),未见其他显著并发症。

核心结论

  • 本研究界定了根治性与姑息性乳腺冷冻消融的治疗成功标准,显示其不仅达到手术(技术)目标也达到患者个体化治疗目标且无显著并发症,可能为将乳腺冷冻消融整合入乳腺癌治疗提供指导。

研究设计与样本

  • 回顾性分析2021—2024年接受乳腺冷冻消融的乳腺癌患者,由乳腺放射科医师在局部麻醉下使用氩气冷冻探针、经超声或MRI引导行门诊冷冻消融。

关键影像表现/征象

  • 消融病灶共34个、来自29例患者,分期为N0M0(25例)、N1M0(2例)、N2M0(1例)、N0M1(1例)。
  • 多数肿瘤为浸润性导管癌(IDC)、低至中级别、雌激素受体(ER)和孕激素受体(PR)阳性且HER2阴性(23个肿瘤,68%)。
  • 根治性冷冻消融肿瘤大小0.4—1.9 cm(中位0.8 cm),姑息性冷冻消融肿瘤大小0.6—6.0 cm(中位1.3 cm)。
  • 27例有随访影像者中,根治性14例共14个肿瘤、姑息性13例共18个病灶;影像随访时间3—26个月(中位16个月),27例中22例、32个肿瘤中25个随访超过12个月。
  • 并发症仅2例皮肤冻伤,1例轻度、1例中度。

诊断标准与关键数值

  • 治疗成功定义为同时达到手术目标和患者个体化治疗目标。
  • 根治性冷冻消融14例中13例达到治疗成功。
  • 姑息性冷冻消融13例全部达到治疗成功。

临床应用与阅片要点

  • 阅片随访时应结合消融分类(根治性或姑息性)及患者个体化治疗目标判断治疗成功。
  • 影像随访需评估消融区变化,随访时间范围3—26个月(中位16个月),多数病例超过12个月。
  • 报告并发症时注意皮肤冻伤,本组出现2例(1例轻度、1例中度)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

RATIONALE AND OBJECTIVES: Recent ICE3 trial of breast cryoablation for breast cancer demonstrated 98% success rate, similar to breast-conserving surgery. However, ICE3 and other published studies did not differentiate curative from palliative treatment nor define patient-specific treatment objectives. We sought to define treatment success of curative and palliative breast cryoablation for breast cancer in meeting procedure objectives and patient-specific treatment objectives.

MATERIALS AND METHODS: We conducted a retrospective analysis of breast cancer patients who underwent breast cryoablation during 2021-2024. Breast radiologists performed outpatient cryoablation using local anesthesia and argon gas cryoprobes under ultrasound or MRI guidance. Patient demographics, referral indications, tumor characteristics, procedure details, and imaging follow-up findings were analyzed. Cryoablation was categorized as curative or palliative. Treatment success was defined as achievement of both procedure and patient-specific treatment objectives.

RESULTS: Breast cryoablation was performed for 34 lesions in 29 patients with N0M0 (n = 25), N1M0 (n = 2), N2M0 (n = 1), and N0M1 (n = 1) disease. Most tumors were invasive ductal carcinoma (IDC), low to intermediate grade, estrogen receptor (ER) and progesterone receptor (PR) positive and HER2 negative (23 tumors, 68%). Tumor size ranged from 0.4-1.9 (median 0.8) cm for curative cryoablation and 0.6-6.0 (median 1.3) cm for palliative cryoablation. For 27 patients with follow-up imaging, ablation was curative in 14 patients, 14 tumors and palliative in 13 patients, 18 lesions. Imaging follow-up time ranged from 3 to 26 (median 16) months, > 12 months in 22 of 27 patients and 25 of 32 tumors. Complications were limited to 2 cases of skin frost injury, 1 mild and 1 moderate. Treatment success was achieved in 13 of 14 patients with curative and all 13 patients with palliative cryoablation.

CONCLUSION: Our study defines treatment success for curative and palliative breast cryoablation, demonstrates breast cryoablation achieves not only procedure (technical) but also patient-specific treatment objectives without significant complications, and may serve as guide for integrating breast cryoablation in the treatment of breast cancer patients.

来源:Acad Radiol,查看原文。版权归原作者所有。

引用

  1. Huang ML, Lane DL, Chang Sen LQ, et al. Defining Breast Cryoablation Treatment Success: A Guide for the Curative and Palliative Treatment of Breast Cancer. Acad Radiol. 2024. PMID: 39107186. doi:10.1016/j.acra.2024.07.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。